Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 express...

Full description

Bibliographic Details
Main Authors: Adi Horesh, Rena Pollack, Hovav Nechushtan, Rivka Dresner-Pollak, Tzahi Neuman
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Pathology and Oncology Research
Subjects:
PD-L1
NSCLC
immune checkpoint inhibitors
immune-related adverse events
thyroid
Online Access:https://www.por-journal.com/articles/10.3389/pore.2023.1610951/full

Similar Items

Similar Items